About Our Team

The Mercy Story

The seeds of Mercy were planted in 2010 when Paul Blavin, financier and philanthropist, met a brilliant freshman enrolled in the Blavin Scholars Program at the University of Michigan named Joseph Sedlak.

With Paul’s support, Joseph graduated summa cum laude from the University of Michigan and entered the combined MD/PhD Program at Harvard and MIT, along the way becoming Paul’s adopted son. During his graduate work, Joseph identified early detection as an area of significant unmet need in the fight to reduce cancer associated morbidity and mortality.

Together Paul and Joseph founded Mercy BioAnalytics in 2018 based on a novel idea: leveraging tumor-derived single extracellular vesicles for early cancer detection. Their mission-driven approach and commitment to creative, rigorous science has drawn a stellar group of investors, colleagues, advisors, and Board members, and the Mercy team remains steadfast in our commitment to their original vision.

The Mercy Story

The seeds of Mercy were planted in 2010 when Paul Blavin, financier and philanthropist, met a brilliant freshman enrolled in the Blavin Scholars Program at the University of Michigan named Joseph Sedlak.

With Paul’s support, Joseph graduated summa cum laude from the University of Michigan and entered the combined MD/PhD Program at Harvard and MIT, along the way becoming Paul’s adopted son. During his graduate work, Joseph identified early detection as an area of significant unmet need in the fight to reduce cancer associated morbidity and mortality.

Together Paul and Joseph founded Mercy BioAnalytics in 2018 based on a novel idea: leveraging tumor-derived single extracellular vesicles for early cancer detection. Their mission-driven approach and commitment to creative, rigorous science has drawn a stellar group of investors, colleagues, advisors, and Board members, and the Mercy team remains steadfast in our commitment to their original vision.

 

Founding pair

Leadership

Dawn Mattoon, PhD

Dawn Mattoon, PhD

Chief Executive Officer

Diane Marcou

Diane Marcou

Chief Financial Officer

Toumy Guettouche, PhD

Toumy Guettouche, PhD

Chief Scientific Officer

Josh Gralapp

Josh Gralapp

Vice President of Marketing and Strategic Alliances

Michael Smith

Michael Smith

Vice President of Quality, Regulatory, & Clinical Affairs

Tim Membrino

Tim Membrino

Vice President of Program & Portfolio Management

Tatia Troy

Tatia Troy

Chief People Officer

Board of Directors

Stanley Lapidus

Stanley Lapidus

Chairman

Paul Blavin

Paul Blavin

Vice Chairman

Sonja Hoel Perkins

Sonja Hoel Perkins

Paul Meister

Paul Meister

Myla Lai-Goldman, MD

Myla Lai-Goldman, MD

Dawn Mattoon, PhD

Dawn Mattoon, PhD

Advisors

Alberto Gutierrez, PhD

Alberto Gutierrez, PhD

Christine Berg, MD

Christine Berg, MD

David Ransohoff, MD

David Ransohoff, MD

Randy Schekman, PhD

Randy Schekman, PhD

Steven Skates, PhD

Steven Skates, PhD

“Never doubt that a small group of thoughtful, committed citizens can change the world; indeed, it’s the only thing that ever has.”

– Margaret Mead

Unparalleled Innovation.

Real collaboration.

Join Mercy BioAnalytics on our lifesaving mission to detect cancer early when it is most curable

ACCELERATING UNDERSTANDING

For pharmaceutical companies, Mercy Halo offers an opportunity to accelerate clinical development programs through exploratory sample analysis for key tumor-derived biomarkers. Future offerings will include patient screening for clinical trial enrollment and companion diagnostic development to support new drug commercialization.

Mercy BioAnalytics works for companies who want to increase the chances of a drug’s success in clinical trials. Mercy Halo helps identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on previously archived plasma or serum samples.